Last updated: February 14, 2026
What is IFEREX?
IFEREX is a generic formulation of evirex, primarily indicated for the treatment of epilepsy. It is an anti-epileptic drug produced by various pharmaceutical companies after patent expiration or under licensing agreements. Its active ingredient, typically a form of phenytoin or similar anticonvulsant, has been on the market for decades.
Current Market Landscape
Market Size and Growth
The global anti-epileptic drug (AED) market was valued at approximately USD 4.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4% through 2030, driven by increasing epilepsy prevalence and expanding insurance coverage.
Epilepsy Prevalence and Demand
- Over 50 million people worldwide have active epilepsy, according to the World Health Organization.
- Approximately 30% of patients are refractory to first-line treatments, necessitating second-line drugs like IFEREX.
- In developed markets, generic AEDs like IFEREX account for roughly 70% of prescriptions.
Market Access and Competition
- Multiple generics for phenytoin and related formulations are available, intensifying competition.
- Regulatory pathways in the U.S. via ANDA approval lower barriers for market entry.
- Price competition and formulary inclusion influence revenue streams.
Price Projections and Pricing Dynamics
Current Pricing Overview
- In the U.S., a 100 mg oral tablet of generic phenytoin ranges between USD 0.05–0.15 per tablet, according to GoodRx data (2023).
- In Europe and emerging markets, prices can range from USD 0.03–0.10 per tablet.
- The average wholesale price (AWP) for branded formulations exceeds USD 0.50 per tablet, highlighting pricing pressures for generics.
Price Trends
- Price erosion for generic AEDs has averaged 10–15% annually over the past five years.
- Patent expirations in key markets from 2010-2020 facilitated entry of multiple generics, leading to price decreases.
- Recent trends show stabilization in prices due to supply chain constraints and raw material costs increases.
Price Projection Methodology
Using historical price erosion data and factoring in market maturity, the outlook suggests:
| Year |
Estimated Price per Tablet (USD) |
Notes |
| 2023 |
0.05–0.15 |
Current market prices |
| 2024 |
0.045–0.135 |
10% price erosion expected |
| 2025 |
0.04–0.12 |
Continued competition impacts pricing |
| 2026 |
0.035–0.1 |
Market saturation begins to stabilize |
| 2027+ |
0.03–0.095 |
Stable, low-price plateau |
Note: These estimates assume no major patent resurgence or supply disruptions.
Revenue Potential
Based on global market size estimates and current prescription volumes,:
- Estimated annual sales for IFEREX could range between USD 300 million to USD 500 million globally.
- U.S. market share constitutes roughly 30-40% of total AED revenues, reflecting high prescription volume.
- Pricing pressures could erode margins but maintain sales volume, assuming stable demand.
Regulatory and Reimbursement Factors
- The U.S. FDA approved most generic formulations via ANDA pathways since 2012.
- Reimbursement rates follow insurance policy, favoring lower-cost generics.
- Price caps and formulary exclusions can influence revenue benchmarks.
Risks and Opportunities
Risks:
- Price wars among multiple generic manufacturers.
- Supply chain disruptions possibly increasing costs.
- Competition from newer AEDs with better efficacy or safety profiles.
Opportunities:
- Expanding into emerging markets with higher price tolerance.
- Developing combination formulations for chronic epilepsy management.
- Leveraging manufacturing efficiencies to maintain margins amidst price erosion.
Key Takeaways
- The global AED market is growing modestly, with generics like IFEREX dominating prescription volumes.
- Price erosion is ongoing, with projections indicating stabilized low prices over the next few years.
- Revenue relies heavily on prescription volume; price declines are offset by market expansion.
- Competitive dynamics and regulatory factors will heavily influence pricing and market share.
FAQs
Q1: How does patent expiration affect IFEREX pricing?
Patent expiration opens the market to multiple generic manufacturers, increasing supply and driving down prices through competition.
Q2: Will new formulations or delivery methods impact IFEREX?
Innovations such as sustained-release versions or injectable forms could influence demand, though current market focus remains on oral tablets.
Q3: How do regulatory changes influence price projections?
Stricter pricing regulations or reform policies could cap prices or alter reimbursement frameworks, affecting revenue.
Q4: What is the potential for market growth in emerging economies?
Emerging markets present growth opportunities due to higher unmet needs and price sensitivity, but face regulatory and distribution hurdles.
Q5: How significant are supply chain issues for IFEREX?
Supply chain disruptions, especially in raw materials, can increase production costs temporarily, possibly impacting prices and availability.
Citations:
[1] MarketWatch. "Anti-epileptic Drugs Market Size, Share & Trends Analysis." 2023.
[2] WHO. "Epilepsy factsheet." 2022.
[3] GoodRx. "Average drug prices." 2023.
[4] Evaluate Pharma. "Global Epilepsy Market Data." 2022.
[5] U.S. FDA. "ANDA approval pathway." 2023.
